HYENA detects oncogenes activated by distal enhancers in cancer

Anqi Yu1, Ali E Yesilkanal1, Ashish Thakur2

  • 1Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA.

PubMed

Insights

We developed HYENA, a computational tool to find oncogenes activated by enhancer hijacking in cancer. This method identified 108 candidate oncogenes, including non-coding genes like TOB1-AS1, which promotes pancreatic cancer metastasis.

Area of Science:

  • Genomics
  • Cancer Biology
  • Bioinformatics

Background:

  • Somatic structural variations (SVs) can alter genome organization and gene regulation in cancer.
  • Enhancer hijacking, driven by SVs, activates proto-oncogenes, but studies often overlook non-coding genes.
  • Understanding SV-driven oncogene activation is crucial for cancer research.

Purpose of the Study:

  • To develop a computational algorithm (HYENA) for identifying candidate oncogenes (protein-coding and non-coding) activated by enhancer hijacking.
  • To analyze a large cohort of adult tumors to discover novel oncogenes implicated in enhancer hijacking.
  • To investigate the role of specific non-coding genes, such as TOB1-AS1, in cancer progression.

Main Methods:

  • Development of the HYENA computational algorithm integrating whole-genome and transcriptome sequencing data.
  • Application of a rank-based regression model to associate gene expression with somatic SVs.
  • Systematic analysis of 1146 tumors across 25 adult cancer types.

Main Results:

  • Identification of 108 candidate oncogenes activated by enhancer hijacking, including numerous non-coding genes.
  • Discovery of the long non-coding RNA TOB1-AS1 activated by SVs in 10% of pancreatic cancers via 3D genome alterations.
  • Demonstration that high TOB1-AS1 expression promotes cancer cell invasion and metastasis.

Conclusions:

  • HYENA is effective in identifying novel oncogenes, particularly non-coding ones, activated by enhancer hijacking.
  • Genetic alterations in non-coding regions significantly contribute to tumorigenesis and cancer progression.
  • TOB1-AS1 represents a potential therapeutic target in pancreatic cancer due to its role in metastasis.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.0K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K